

## Immunogenic Components of Selected Vaccines <sup>A</sup>

Vaccine		Active Components
Diphtheria, Tetanus, Acellular Pertussis, Hepatitis B, Polio, <i>Haemophilus influenzae</i> type b (DTaP-HB-IPV-Hib)	INFANRIX hexa®	<ul style="list-style-type: none"> <li>• 25 Lf diphtheria toxoid</li> <li>• 10 Lf tetanus toxoid</li> <li>• 25 µg pertussis toxoid</li> <li>• 25 µg filamentous haemagglutinin</li> <li>• 8 µg pertactin</li> <li>• 10 µg hepatitis B surface antigen</li> <li>• Inactivated polio virus: 40 D-antigen units of type 1 (Mahoney strain), 8 D-antigen units of type 2 (MEF-1 strain), and 32 D-antigen units of type 3 (Saukett strain)</li> <li>• 10 µg of Hib polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to 25 µg of tetanus toxoid</li> </ul>
Diphtheria, Tetanus, Acellular Pertussis, Polio, <i>Haemophilus influenzae</i> type b (DTaP-IPV-Hib)	INFANRIX®-IPV/HIB	<ul style="list-style-type: none"> <li>• 25 Lf diphtheria toxoid</li> <li>• 10 Lf tetanus toxoid</li> <li>• 25 µg pertussis toxoid</li> <li>• 25 µg filamentous haemagglutinin</li> <li>• 8 µg pertactin</li> <li>• Inactivated polio virus: 40 D-antigen units of type 1 (Mahoney strain), 8 D-antigen units of type 2 (MEF-1 strain), and 32 D-antigen units of type 3 (Saukett strain)</li> <li>• 10 µg of Hib polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to 25 µg of tetanus toxoid</li> </ul>
	PEDIACEL®	<ul style="list-style-type: none"> <li>• 15 Lf diphtheria toxoid</li> <li>• 5 Lf tetanus toxoid</li> <li>• 20 µg pertussis toxoid</li> <li>• 20 µg filamentous haemagglutinin</li> <li>• 5 µg fimbriae types 2 and 3</li> <li>• 3 µg pertactin</li> <li>• Inactivated polio virus: 40 D-antigen units of type 1 (Mahoney strain), 8 D-antigen units of type 2 (MEF-1 strain), and 32 D-antigen units of type 3 (Saukett strain)</li> <li>• 10 µg of Hib polyribosylribitol phosphate (PRP) capsular polysaccharide conjugated to 18-30 µg of tetanus protein</li> </ul>

<sup>A</sup> For additional information on vaccine components see [Part 4 – Biological Products](#) and [Non-Immunogenic Components of Vaccines](#).

Vaccine		Active Components
<i>Haemophilus influenzae</i> type b (Hib)	Act-HIB®	<ul style="list-style-type: none"> <li>10 µg of Hib polyribosylribitol phosphate (PRP) capsular polysaccharide bound to 18-30 µg of tetanus protein</li> </ul>
	HIBERIX®	<ul style="list-style-type: none"> <li>10 µg of Hib polyribosylribitol phosphate (PRP) capsular polysaccharide covalently bound to approximately 25 µg of tetanus toxoid</li> </ul>
Hepatitis A (HA)	AVAXIM®	<ul style="list-style-type: none"> <li>160 antigen units/0.5 mL of inactivated hepatitis A virus</li> </ul>
	AVAXIM® Pediatric	<ul style="list-style-type: none"> <li>80 antigen units/0.5 mL of inactivated hepatitis A virus</li> </ul>
	HAVRIX® 1440	<ul style="list-style-type: none"> <li>1440 ELISA units/1 mL of inactivated hepatitis A virus</li> </ul>
	HAVRIX® 720 Junior	<ul style="list-style-type: none"> <li>720 ELISA units/0.5 mL of inactivated hepatitis A virus</li> </ul>
	VAQTA®	<ul style="list-style-type: none"> <li>Adult presentation: 50 U/1 mL of hepatitis A virus protein</li> <li>Pediatric presentation: 25 U/0.5 mL of hepatitis A virus protein</li> </ul>
Hepatitis A and B Combined (HAHB)	TWINRIX®	<ul style="list-style-type: none"> <li>720 ELISA units inactivated hepatitis A virus and 20 µg hepatitis B surface antigen per 1 mL</li> </ul>
	TWINRIX® Junior	<ul style="list-style-type: none"> <li>360 ELISA units inactivated hepatitis A virus and 10 µg hepatitis B surface antigen per 0.5 mL</li> </ul>
Hepatitis B (HB)	ENGERIX®-B	<ul style="list-style-type: none"> <li>Adult presentation: 20 µg/1 mL of hepatitis B surface antigen</li> <li>Pediatric presentation: 10 µg/0.5 mL of hepatitis B surface antigen</li> </ul>
	RECOMBIVAX HB®	<ul style="list-style-type: none"> <li>Adult presentation: 10 µg/1 mL of hepatitis B surface antigen</li> <li>Dialysis presentation: 40 µg/1 mL of hepatitis B surface antigen</li> <li>Pediatric presentation: 5 µg/0.5 mL of hepatitis B surface antigen</li> </ul>
Human Papillomavirus (HPV)	GARDASIL®9	<ul style="list-style-type: none"> <li>30 µg HPV type 6 L1 protein</li> <li>40 µg HPV type 11 L1 protein</li> <li>60 µg HPV type 16 L1 protein</li> <li>40 µg HPV type 18 L1 protein</li> <li>20 µg HPV type 31 L1 protein</li> <li>20 µg HPV type 33 L1 protein</li> <li>20 µg HPV type 45 L1 protein</li> <li>20 µg HPV type 52 L1 protein</li> <li>20 µg HPV type 58 L1 protein</li> </ul>

Vaccine		Active Components
	CERVARIX®	<ul style="list-style-type: none"> <li>• 20 µg HPV type 16 L1 protein</li> <li>• 20 µg HPV type 18 L1 protein</li> </ul>
Measles, Mumps, Rubella (MMR)	MMR® II	<ul style="list-style-type: none"> <li>• ≥ 1000 CCID<sub>50</sub> of measles virus (Enders' Edmonston strain)</li> <li>• ≥ 5000 CCID<sub>50</sub> of mumps virus (Jeryl Lynn (B level) strain)</li> <li>• ≥ 1000 CCID<sub>50</sub> rubella virus (Wistar RA 27/3 strain)</li> </ul>
	PRIORIX®	<ul style="list-style-type: none"> <li>• ≥ 10<sup>3</sup> CCID<sub>50</sub> measles virus (Schwarz strain)</li> <li>• ≥ 10<sup>3.7</sup> CCID<sub>50</sub> mumps virus (RIT 4385 strain)</li> <li>• ≥ 10<sup>3</sup> CCID<sub>50</sub> rubella virus (Wistar RA 27/3 strain)</li> </ul>
Measles, Mumps, Rubella, Varicella (MMRV)	PRIORIX-TETRA®	<ul style="list-style-type: none"> <li>• ≥ 10<sup>3</sup> CCID<sub>50</sub> measles virus (Schwarz strain)</li> <li>• ≥ 10<sup>4.4</sup> CCID<sub>50</sub> mumps virus (RIT 4385 strain)</li> <li>• ≥ 10<sup>3</sup> CCID<sub>50</sub> rubella virus (Wistar RA 27/3 strain)</li> <li>• ≥ 10<sup>3.3</sup> PFU varicella virus (Oka strain)</li> </ul>
	PROQUAD®	<ul style="list-style-type: none"> <li>• ≥ 10<sup>3</sup> TCID<sub>50</sub> of measles virus (Enders' Edmonston strain)</li> <li>• ≥ 10<sup>4.3</sup> TCID<sub>50</sub> of mumps virus (Jeryl Lynn (B level) strain)</li> <li>• ≥ 10<sup>3</sup> TCID<sub>50</sub> rubella virus (Wistar RA 27/3 strain)</li> <li>• ≥ 10<sup>3.99</sup> PFU of varicella zoster virus (Oka/Merck strain)</li> </ul>
Meningococcal B (Men B)	BEXSERO®	<ul style="list-style-type: none"> <li>• 50 µg Neisserial heparin binding antigen fusion protein</li> <li>• 50 µg <i>Neisseria</i> adhesin A protein</li> <li>• 50 µg factor H binding protein fusion protein</li> <li>• 25 µg outer membrane vesicles containing Por A protein from <i>N. meningitidis</i> serogroup B</li> </ul>
Meningococcal C Conjugate (Men-C-C)	NEISVAC-C®	<ul style="list-style-type: none"> <li>• 10 µg <i>Neisseria meningitidis</i> group C polysaccharide conjugated to 10-20 µg tetanus toxoid</li> </ul>
Meningococcal Quadrivalent Conjugate (Men-C-ACYW-135)	MENACTRA®	<ul style="list-style-type: none"> <li>• 4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg diphtheria toxoid protein carrier</li> </ul>
	MENVEO®	<ul style="list-style-type: none"> <li>• 5 µg each of meningococcal C, W-135, and Y oligosaccharides and 10 µg of meningococcal A oligosaccharide conjugated to approximately 47 µg of diphtheria CRM<sub>197</sub> protein</li> </ul>
	NIMENRIX®	<ul style="list-style-type: none"> <li>• 5 µg each of meningococcal A, C, Y and W-135 polysaccharides conjugated to 44 µg of tetanus toxoid carrier protein</li> </ul>

Vaccine		Active Components
Pneumococcal Conjugate (PCV13)	PREVNAR® 13	<ul style="list-style-type: none"> <li>2.2 µg of each saccharide from <i>Streptococcus pneumoniae</i> serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F and 4.4 µg of saccharide from serotype 6B individually conjugated to 34 µg diphtheria CRM<sub>197</sub> protein</li> </ul>
Pneumococcal Polysaccharide (PPV23)	PNEUMOVAX® 23	<ul style="list-style-type: none"> <li>25 µg each of capsular polysaccharides from <i>Streptococcus pneumoniae</i> serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F</li> </ul>
Polio (IPV)	IMOVAX® POLIO	<ul style="list-style-type: none"> <li>Inactivated polio virus: 40 D-antigen units of type 1 (Mahoney strain), 8 D-antigen units of type 2 (MEF-1 strain), and 32 D-antigen units of type 3 (Saukett strain)</li> </ul>
Rabies	IMOVAX® Rabies	<ul style="list-style-type: none"> <li>≥ 2.5 IU/1 mL rabies virus (WISTAR Rabies PM/WI 38 1503-3M strain)</li> </ul>
	RabAvert®	<ul style="list-style-type: none"> <li>≥ 2.5 IU/1 mL rabies antigen (Flury LEP strain)</li> </ul>
Rotavirus (Rota)	ROTARIX®	<ul style="list-style-type: none"> <li>10<sup>6</sup> CCID<sub>50</sub> human rotavirus (RIX4414 strain)</li> </ul>
	RotaTeq®	<ul style="list-style-type: none"> <li>Human-bovine reassortant rotavirus strains:               <ul style="list-style-type: none"> <li>2.2×10<sup>6</sup> infectious units type G1</li> <li>2.8×10<sup>6</sup> infectious units type G2</li> <li>2.2×10<sup>6</sup> infectious units type G3</li> <li>2.0×10<sup>6</sup> infectious units type G4</li> <li>2.3×10<sup>6</sup> infectious units type P1A[8]</li> </ul> </li> </ul>
Tetanus, Diphtheria (Td)	Td Adsorbed	<ul style="list-style-type: none"> <li>5 Lf tetanus toxoid</li> <li>2 Lf diphtheria toxoid</li> </ul>
Tetanus, Diphtheria, Acellular Pertussis (Tdap)	ADACEL®	<ul style="list-style-type: none"> <li>5 Lf tetanus toxoid</li> <li>2 Lf diphtheria toxoid</li> <li>2.5 µg pertussis toxoid</li> <li>5 µg filamentous haemagglutinin</li> <li>5 µg fimbriae types 2 and 3</li> <li>3 µg pertactin</li> </ul>
	BOOSTRIX®	<ul style="list-style-type: none"> <li>5 Lf tetanus toxoid</li> <li>2.5 Lf diphtheria toxoid</li> <li>8 µg pertussis toxoid</li> <li>8 µg filamentous haemagglutinin</li> <li>2.5 µg pertactin</li> </ul>

Vaccine		Active Components
Tetanus, Diphtheria, Acellular Pertussis, Polio (Tdap-IPV)	ADACEL®-POLIO	<ul style="list-style-type: none"> <li>• 5 Lf tetanus toxoid</li> <li>• 2 Lf diphtheria toxoid</li> <li>• 2.5 µg pertussis toxoid</li> <li>• 5 µg filamentous haemagglutinin</li> <li>• 5 µg fimbriae types 2 and 3</li> <li>• 3 µg pertactin</li> <li>• Inactivated polio virus: 40 D-antigen units of type 1 (Mahoney strain), 8 D-antigen units of type 2 (MEF-1 strain), and 32 D-antigen units of type 3 (Saukett strain)</li> </ul>
	BOOSTRIX®-POLIO	<ul style="list-style-type: none"> <li>• 5 Lf tetanus toxoid</li> <li>• 2.5 Lf diphtheria toxoid</li> <li>• 8 µg pertussis toxoid</li> <li>• 8 µg filamentous haemagglutinin</li> <li>• 2.5 µg pertactin</li> <li>• Inactivated polio virus: 40 D-antigen units of type 1, 8 D-antigen units of type 2, and 32 D-antigen units of type 3</li> </ul>
Tetanus, Diphtheria, Polio (Td/IPV)	Td Polio Adsorbed	<ul style="list-style-type: none"> <li>• 5 Lf tetanus toxoid</li> <li>• 2 Lf diphtheria toxoid</li> <li>• Inactivated polio virus: 40 D-antigen units of type 1 (Mahoney strain), 8 D-antigen units of type 2 (MEF 1 strain), and 32 D-antigen units of type 3 (Saukett strain)</li> </ul>
Varicella (Var)	VARILRIX®	<ul style="list-style-type: none"> <li>• ≥ 10<sup>3.3</sup> PFU varicella zoster virus (Oka strain)</li> </ul>
	VARIVAX® III	<ul style="list-style-type: none"> <li>• ≥ 1350 PFU varicella zoster virus (Oka/Merck strain)</li> </ul>
Zoster	SHINGRIX®	<ul style="list-style-type: none"> <li>• 50 µg varicella zoster virus glycoprotein E</li> </ul>
	ZOSTAVAX® II	<ul style="list-style-type: none"> <li>• ≥ 19,400 PFU varicella zoster virus (Oka/Merck strain)</li> </ul>